EC HEALTHCARE |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.19 HKD | 0.00% |
|
-1.65% | -31.61% |
| Jun. 27 | EC Healthcare Does Not Recommends Final Dividend for the Year Ended 31 March 2024 | CI |
| Jun. 27 | EC Healthcare Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
Valuation
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 5,539 | 3,350 | 7,261 | 9,828 | 7,431 | 1,410 | - | - |
| Enterprise Value (EV) 1 | 5,539 | 3,091 | 6,853 | 9,191 | 7,431 | 1,553 | 1,411 | 1,410 |
| P/E ratio | 16 x | 11.7 x | 36.3 x | 49.6 x | 106 x | -81.9 x | 6.85 x | 4.33 x |
| Yield | 5.99% | 6.76% | 2.35% | 1.73% | 1.59% | 3.32% | 6.08% | 8.87% |
| Capitalization / Revenue | 3.02 x | 1.72 x | 3.49 x | 3.37 x | 1.92 x | 0.37 x | 0.28 x | 0.24 x |
| EV / Revenue | 3.02 x | 1.59 x | 3.29 x | 3.15 x | 1.92 x | 0.37 x | 0.28 x | 0.24 x |
| EV / EBITDA | 11 x | 5.04 x | 11.5 x | 11.4 x | 7.99 x | 2.1 x | 1 x | 0.91 x |
| EV / FCF | -71.1 x | 6.1 x | 14.1 x | 26.4 x | 38.3 x | 4.17 x | 3.41 x | 1.52 x |
| FCF Yield | -1.41% | 16.4% | 7.08% | 3.79% | 2.61% | 24% | 29.4% | 65.6% |
| Price to Book | 5.51 x | 3.34 x | 5.72 x | 5.22 x | 4.01 x | 0.79 x | 0.75 x | 0.66 x |
| Nbr of stocks (in thousands) | 948,524 | 985,277 | 1,071,016 | 1,178,372 | 1,185,211 | 1,185,211 | - | - |
| Reference price 2 | 5.840 | 3.400 | 6.780 | 8.340 | 6.270 | 1.190 | 1.190 | 1.190 |
| Announcement Date | 6/26/19 | 6/29/20 | 6/29/21 | 6/23/22 | 6/23/23 | 6/27/24 | - | - |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: Marzo | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,837 | 1,949 | 2,080 | 2,920 | 3,875 | 4,211 | 5,103 | 5,943 |
| EBITDA 1 | 501.5 | 613 | 594.4 | 804.5 | 929.8 | 737.8 | 1,416 | 1,555 |
| EBIT 1 | 452.5 | 543.1 | 284.6 | 371 | 187.5 | 112.3 | 423.4 | 589 |
| Operating Margin | 24.64% | 27.87% | 13.68% | 12.71% | 4.84% | 2.67% | 8.3% | 9.91% |
| Earnings before Tax (EBT) 1 | 450.1 | 360.5 | 265.9 | 321.4 | 136.2 | 16.87 | 335.6 | 508.1 |
| Net income 1 | 361.1 | 286.6 | 192.9 | 197.5 | 69.65 | -18.95 | 205.2 | 325.8 |
| Net margin | 19.66% | 14.71% | 9.27% | 6.76% | 1.8% | -0.45% | 4.02% | 5.48% |
| EPS 2 | 0.3660 | 0.2900 | 0.1870 | 0.1680 | 0.0590 | -0.0160 | 0.1738 | 0.2750 |
| Free Cash Flow 1 | -77.94 | 506.7 | 484.9 | 348.1 | 194.3 | 338.4 | 414 | 925 |
| FCF margin | -4.24% | 26% | 23.31% | 11.92% | 5.01% | 7.91% | 8.11% | 15.57% |
| FCF Conversion (EBITDA) | - | 82.65% | 81.58% | 43.27% | 20.89% | 28.43% | 29.23% | 59.5% |
| FCF Conversion (Net income) | - | 176.81% | 251.44% | 176.25% | 278.9% | 715.2% | 201.77% | 283.89% |
| Dividend per Share 2 | 0.3500 | 0.2300 | 0.1590 | 0.1440 | 0.1000 | 0.0395 | 0.0723 | 0.1055 |
| Announcement Date | 6/26/19 | 6/29/20 | 6/29/21 | 6/23/22 | 6/23/23 | 6/27/24 | - | - |
1HKD in Million2HKD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: March | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S2 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|
| Net sales | 1,118 | 830 | 797.4 | 1,283 | 1,444 | 1,476 | 1,982 | - |
| EBITDA | - | 241.1 | - | 399.3 | 323.2 | - | - | - |
| EBIT | - | 205.6 | - | 215.1 | 248.6 | - | - | - |
| Operating Margin | - | 24.77% | - | 16.76% | 17.22% | - | - | - |
| Earnings before Tax (EBT) | - | 111.6 | - | 205 | 231.7 | 89.69 | - | - |
| Net income | - | 89.07 | - | 148.9 | 160.2 | 37.29 | -10.39 | - |
| Net margin | - | 10.73% | - | 11.61% | 11.1% | 2.53% | -0.52% | - |
| EPS 1 | 0.2000 | 0.0900 | - | - | 0.1400 | 0.0280 | - | 0.0300 |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 11/26/19 | 6/29/20 | 11/26/20 | 6/29/21 | 11/29/21 | 6/23/22 | 6/23/23 | - |
1HKD
Estimates
Balance Sheet Analysis
| Fiscal Period: March | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | 0.1 | 0.1 | - |
| Net Cash position 1 | - | 258 | 409 | 637 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | 0.000084 x | 0.000071 x | - |
| Free Cash Flow 1 | -77.9 | 507 | 485 | 348 | 194 | 338 | 414 | 925 |
| ROE (net income / shareholders' equity) | 38.8% | 28% | 17% | 12.5% | 3.73% | 2.73% | 8.5% | 11.8% |
| ROA (Net income/ Total Assets) | 16.7% | 11.7% | 6.08% | 4.57% | 1.34% | 4.93% | 8.75% | 15.9% |
| Assets 1 | 2,165 | 2,451 | 3,173 | 4,326 | 5,187 | 959.1 | 2,345 | 2,049 |
| Book Value Per Share 2 | 1.060 | 1.020 | 1.180 | 1.600 | 1.560 | 1.500 | 1.580 | 1.800 |
| Cash Flow per Share 2 | - | 0.5800 | 0.6000 | 0.5200 | - | 0.5700 | 0.7600 | - |
| Capex 1 | 316 | 69.8 | 136 | 260 | 411 | 692 | 735 | 750 |
| Capex / Sales | 17.23% | 3.58% | 6.53% | 8.91% | 10.61% | 16.16% | 14.4% | 12.62% |
| Announcement Date | 6/26/19 | 6/29/20 | 6/29/21 | 6/23/22 | 6/23/23 | 6/27/24 | - | - |
1HKD in Million2HKD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
1.19
HKD
Average target price
2.103
HKD
Spread / Average Target
+76.75%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -31.61% | 181M | |
| +38.27% | 470M | |
| -20.00% | 415M | |
| -17.89% | 233M | |
| -15.47% | 103M | |
| +88.38% | 94.58M | |
| -0.43% | 81.99M | |
| -11.48% | 69.42M | |
| -1.92% | 60.62M | |
| -20.69% | 58.9M |
- Stock Market
- Equities
- 2138 Stock
- Financials EC Healthcare
